iiinova — where your digital self keeps evolving

VJHemOnc @vjhemonc.bsky.social · 19/03/2026

There's still time to register for #EBMT26!🩸 Hear from Anna Sureda, the President of @theebmt.bsky.social, who shares insight into this fantastic event & invites you to join: 🎥 👉 buff.ly/oixK5Pq Can't make it to Madrid? You can register to attend virtually instead! Click here: ➡️ buff.ly/ahhtftc

011

Reposted by VJHemOnc

EBMT @theebmt.bsky.social · 11/03/2026

Excitement is building for #EBMT26! 🌟🔜 From 22-25 March 2026, #Madrid 🇪🇸 will host thousands of HCP's and innovators. 🚀 Attend in-person, secure a Day Pass or join virtually and access recordings until 25 April 2026. 🎫 Register now ⬇️ www.ebmt.org/annual-meeting/register

032

Reposted by VJHemOnc

EBMT @theebmt.bsky.social · 06/03/2026

EBMT 2026 is around the corner! 🔜 #EBMT26 Join thousands of HCP's in #Madrid 🇪🇸 from 22-25 March 2026. 🤩 📍 Attend in person 🎫 Get a Day Pass 💻 Or join virtually Register here ➡️🔗 www.ebmt.org/annual-meeting-2026

012

VJHemOnc @vjhemonc.bsky.social · 05/03/2026

We're thrilled to be an official media partner for #EBMT26, and we can't wait to be on-site once again, filming our expert video interviews! 🎥🩸 Interested in joining us there or attending virtually? Click here to register now: ➡️ buff.ly/bWxuru2 #BMTsm #HemOnc #ImmunoOnc @theebmt.bsky.social

011

VJHemOnc @vjhemonc.bsky.social · 23/02/2026

Want to find out about the latest updates and advances in transplantation and cellular therapy?🩸 Then you won't want to miss the 52nd Annual Meeting of the EBMT taking place 22–25 March in Madrid, Spain, & online.🇪🇸💻 Register here: ➡️ buff.ly/0fBo0ka #EBMT26 #HemOnc #BMTsm @theebmt.bsky.social

ow.ly

Official Registration to EBMT 2026

Sign up to attend the 52nd Annual Meeting of the EBMT in-person in Madrid or virtually. Get the best rate by registering before the Early Bird deadline on 19 January 2026.

011

VJHemOnc @vjhemonc.bsky.social · 05/02/2026

Just one week to go until #CART26 kicks off in Palma de Mallorca, Spain, and online!🇪🇸 💻 Hear from the meeting chair, Annalisa Ruggeri, who encourages you to register for this hybrid meeting: 🎥 buff.ly/poXdp9x Register here: ➡️ buff.ly/LMXQ0qU.. #CARTCell #ImmunoOnc #HemOnc @theebmt.bsky.social

010

VJHemOnc @vjhemonc.bsky.social · 29/01/2026

Have you registered for #CART26 yet?🩸 Hear from @alexrampotas.bsky.social, who highlights the importance of the meeting as a platform for exchanging ideas & showcasing new data in the field of CAR-T & cellular therapy: 🎥 buff.ly/WhO2pQl Register here: 👉 buff.ly/NBpWzCH @theebmt.bsky.social

022

VJHemOnc @vjhemonc.bsky.social · 19/01/2026

Want to find out about the latest advances in #CARTCell therapy?🩸💉 Register for the EBMT-EHA 8th European CAR T-cell Meeting taking place next month, and stay tuned for our exclusive coverage of this fantastic event!🎥 Click here to register: 👉 buff.ly/kVxJ8jg.. 👈 #CART26 @theebmt.bsky.social

021

VJHemOnc @vjhemonc.bsky.social · 08/01/2026

We are thrilled to be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, taking place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸 Want to join us there or attend virtually? Register here: 👉 buff.ly/HFpKa82.. #CARTCell #CART26 @theebmt.bsky.social

011

VJHemOnc @vjhemonc.bsky.social · 11/11/2025

In an interview from #iwCLL2025, Nicolas Martinez-Calle provides insight into the UNCOVER project, which aims to evaluate inequalities in the diagnosis and survival of patients with CLL in England. Watch here: 👉 buff.ly/FZdouqO 👈 #CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 11/11/2025

🩸🎥 Approaching TP53-mutated AML: current challenges, ongoing research & novel therapeutic strategies. Don't miss this insightful roundtable discussion from #iwAL25 with leading experts Eunice Wang, David Sallman, Gabriel Mannis, & Andrew Wei. Watch now: 👉 buff.ly/VJJUbmz #AMLsm #Leusm #Leukemia

020

VJHemOnc @vjhemonc.bsky.social · 10/11/2025

At #IMS25, we spoke with Lisa Leypoldt, who shared findings from the cytogenetic subgroup analyses of the Phase II GMMG-CONCEPT trial evaluating Isa-KRd in newly diagnosed #myeloma. Click here to watch: 🎥 buff.ly/Ut0Ne7p #MMSM #MultipleMyeloma #CTSM #ImmunoOnc #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 09/11/2025

Thank you to Ali Taher for speaking with us recently and providing valuable insight into the management of acute complications of #thalassemia that may present to the emergency department. Watch the interview here: 👉 buff.ly/yL0drrc 👈 #Hematology #BloodSky #HemeSky #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 08/11/2025

🎥 Vanthana Bharathi of @mdanderson.bsky.social discusses optimizing preventive care for patients with CLL using evidence-based strategies: 👉 buff.ly/BKMPQGT 👈 #CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 07/11/2025

In an interview from #SOHO2025, @krishpatelmd.bsky.social of @scri.com comments on the potential of NK cell-based therapies for B-cell lymphomas. Click here to watch: 👉 buff.ly/jMYSlMT 👈 #LYMsm #Lymphoma #HemOnc #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 07/11/2025

🎥 Asya Varshavsky-Yanovsky shares insight into a study showing that a high peak in absolute lymphocyte count following cilta-cel infusion in patients with #myeloma predicts for increased risk of delayed neurological toxicities: 👉 buff.ly/MjL0Oku 👈 #CARTcell #MMSM #MultipleMyeloma #ImmunoOnc #IMS25

010

VJHemOnc @vjhemonc.bsky.social · 06/11/2025

Recently, Gottfried von Keudell shared the long-term follow-up results from the Phase II ELM-2 study evaluating the efficacy of the bispecific antibody odronextamab in patients with R/R #FollicularLymphoma. Watch here: 👉 buff.ly/6GUNfkY 👈 #ImmunoOnc #LYMsm #CTSM #TrialUpdate #SOHO2025 #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 06/11/2025

What are the key risk factors for the development of bone disease in patients with #thalassemia? 🩸🦴 Julian Waung provided insight into this in a recent interview – watch here: 👉 buff.ly/Oe2kknT 👈 #Hematology #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 05/11/2025

At #iwNHL25, Alexey Danilov of @cityofhope.bsky.social and Meghan Thompson of @mskcancercenter.bsky.social sat down to provide an update on BTK-targeting therapies in non-Hodgkin #lymphoma and CLL.🩸 This is a discussion you don't want to miss! Click here: 🎥 buff.ly/t3TZTiT #LYMsm #HemOnc

021

VJHemOnc @vjhemonc.bsky.social · 05/11/2025

The IMPROVE trial compared the impact of paused versus continuous BTKi therapy during vaccination in patients with CLL.🩸💉 We recently had the pleasure of speaking to Helen Parry to find out more about the study: 🎥 buff.ly/j1K0VV8 #CLLsm #Leusm #Leukemia #CTSM #iwCLL2025 #ImmunoOnc

000

VJHemOnc @vjhemonc.bsky.social · 04/11/2025

Check out this fantastic discussion with #lymphoma experts Martin Dreyling & Georg Hess, who discuss key advances in MCL treatment. Topics covered: 🔸 The TRIANGLE trial 🔸 The role of novel agents 🔸 Treatment approaches for frontline and relapsed disease 👉 buff.ly/QbNZjR2 #LymSM #HemOnc

000

VJHemOnc @vjhemonc.bsky.social · 04/11/2025

🎥 Mazyar Shadman of @fredhutch.org presents the results of a post hoc analysis & MAIC comparing the outcomes of fit patients treated with zanubrutinib in the SEQUOIA trial to the outcomes of patients treated with AV in AMPLIFY: 👉 buff.ly/paPH5vx 👈 #CLLsm #iwCLL2025 #Leusm #CTSM #BloodSky #HemeSky

010

VJHemOnc @vjhemonc.bsky.social · 03/11/2025

It was fantastic to catch up with @jmikhaelmd.bsky.social at #SOHO2025 to gain insight into areas of consensus & controversy in the current & future management of R/R #MultipleMyeloma!🩸 Watch the interview here: 👉 buff.ly/7AoA6tc 👈 #MMsm #Myeloma #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 02/11/2025

In an interview from #iwAL25, Tara Lin discusses the possibility of tailoring treatment for secondary AML dependent on mutational profile, highlighting the heterogeneity of this disease. Watch here: 👉 buff.ly/HbJTfmF 👈 #AMLsm #Leusm #Leukemia #HemOnc #BloodSky

000

VJHemOnc @vjhemonc.bsky.social · 01/11/2025

It was great to catch up with the wonderful Anna Schuh at #iwCLL2025 to hear about ongoing efforts to improve the outcomes & care of patients with CLL in resource-limited settings. Watch the interview here: 🎥 buff.ly/sZGLLe2 #CLLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 31/10/2025

We recently had the pleasure of interviewing the lovely Payal Desai to hear about several topics in the field of #SickleCellDisease, including the potential of the six-minute walk test as a prognostic tool. 🚶 Learn more here: 👉 buff.ly/iMa7wAa #Hematology #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 31/10/2025

Want to gain insight into the use of bispecific antibodies & other immunotherapies in early lines of treatment for #NonHodgkinLymphoma?🩸 Check out our discussion from #iwNHL25, with leading experts @DocHutchings, @elizabeth_budde, Lorenzo Falchi, & Sameh Gaballa: 🎥 buff.ly/CPiM5kC #LYMsm #HemOnc

010

VJHemOnc @vjhemonc.bsky.social · 30/10/2025

In a recent interview, Jesús San Miguel comments on the updated findings of the Phase III GEM2017FIT trial, which evaluated the efficacy of DaraKRd versus KRd in patients with newly diagnosed #MultipleMyeloma. Click to watch: 👉 buff.ly/RVZjPoG 👈 #CTSM #TrialUpdate #IMS25 #MMsm #Myeloma #BloodSky

000

VJHemOnc @vjhemonc.bsky.social · 30/10/2025

What should the optimal pre-transfusion hemoglobin target be in patients with thalassemia? 🤔🩸 We caught up with Maria Domenica Cappellini recently to find out! Click here to watch the interview: 🎥 👉 buff.ly/B8HDjTL #Thalassemia #Hematology #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 29/10/2025

#iwAL25 | John DiPersio comments on the challenges of treating T-cell malignancies with bispecific antibody therapy, and shares insights into the development of WU-CART-007, an anti-CD7 allogeneic CAR T-cell product: 🎥 buff.ly/s2zXiCa #ALLsm #Leusm #ImmunoOnc #HemOnc #BloodSky #HemeSky #MedSky

020

VJHemOnc @vjhemonc.bsky.social · 29/10/2025

It was fantastic to catch up with the lovely Meral Beksac at #IMS25 to hear about strategies for improving CAR T-cell responsiveness and overcoming resistance in patients with #MultipleMyeloma. Watch the interview here: 🎥 buff.ly/Rm44VmO #MMsm #Myeloma #CARTCell #ImmunoOnc #BloodSky #HemeSky

000

VJHemOnc @vjhemonc.bsky.social · 28/10/2025

How should physicians approach the management of patients with CLL who relapse following treatment with a triplet regimen? 💭🩸 Jacob Soumerai discussed this in a recent interview: 🎥 buff.ly/6qCplqB #CLLsm #Leusm #iwCLL2025 #HemOnc #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 27/10/2025

At #SOHO2025, Asfand Yar Cheema of @clevelandclinic.bsky.social stopped by to share insights into the clinical outcomes of patients with #PolycythemiaVera or MDS treated with GLP-1 agonists. Click here to watch the interview: 👉 buff.ly/KcqIbrj 👈 #MDSsm #MPNsm #HemOnc #BloodSky #HemeSky #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 26/10/2025

In an interview from #IMS25, Doris Hansen of @moffittnews.bsky.social outlined the results from a CIBMTR study assessing the safety and efficacy of cilta-cel in R/R #MultipleMyeloma.💉🩸 Watch here: 👉 buff.ly/fMxLmKd 👈 #IMS25 #MMsm #Myeloma #ImmunoOnc #CARTCell @myeloma-society.bsky.social

000

VJHemOnc @vjhemonc.bsky.social · 25/10/2025

As today is World MDS Awareness Day, why not check out our MDS channel?🩸 You'll find the latest updates in MDS straight from leading experts in the form of video interviews, roundtable discussions, feature articles, podcasts, & more!🎥🎧 Click here to explore: 👉 buff.ly/aWAEu6k #MDSWAD2025 #MDSsm

000

VJHemOnc @vjhemonc.bsky.social · 25/10/2025

Today is MDS World Awareness Day!🩸🌎 In an interview from earlier this year, Valeria Santini discussed the use of immunosuppressive therapy in MDS, highlighting available agents & areas for further research: 👉 buff.ly/OsY3ebW 👈 #MDSWAD2025 #HemOnc #MDSsm #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 24/10/2025

🎥 Moritz Fürstenau comments on the optimal duration of time-limited BTK inhibitor plus BCL2 inhibitor combination therapy in CLL: 👉 buff.ly/BiuqDZd 👈 #CLLsm #Leusm #Leukemia #HemOnc #iwCLL2025 #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 23/10/2025

In a fantastic discussion from #iwNHL25, Stephen Ansell, Michael Wang & Tycel Phillips provide updates on the management of #MantleCellLymphoma. The experts discuss frontline therapy, the evolving role of autoSCT, treatment sequencing, & the value of MRD. Watch here: 👉 buff.ly/oAIf6YW 👈 #LYMsm

000

VJHemOnc @vjhemonc.bsky.social · 22/10/2025

We recently spoke with Karthik Ramasamy, who shared insight into the DREAMM-9 trial, aimed at optimizing the dose of belantamab mafodotin for the treatment of transplant-ineligible newly diagnosed #MultipleMyeloma. Watch here: 👉 buff.ly/szIDc29 #Myeloma #MMSM #HemOnc #CTSM #TrialUpdate #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 21/10/2025

🎥 In an insightful recent interview, Alexandra Gomez-Arteaga of @weillcornell.bsky.social discusses the future of stem cell transplantation for hematological malignancies, highlighting three promising studies that aim to improve outcomes for patients: 👉 buff.ly/uWqWX4z 👈 #BMTsm #HemOnc #SOHO2025

000

VJHemOnc @vjhemonc.bsky.social · 21/10/2025

Want to hear highlights from #iwAL25?🩸 Check out our fantastic roundtable discussion with leading experts Harry Erba, Thomas Cluzeau, Marina Konopleva, & Aditi Shastri by clicking here: 👉 buff.ly/wtheBJa 👈 #AMLsm #Leusm #Leukemia #HemOnc #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 20/10/2025

Want to hear findings from the EPCORE NHL-2 trial evaluating epcoritamab plus intensive chemo for patients with R/R #DLBCL eligible for autoSCT? Watch our interview with Marek Trněný of @charlesuni.cuni.cz from #SOHO2025: 👉 buff.ly/GHh6dYG 👈 #LYMsm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky

011

VJHemOnc @vjhemonc.bsky.social · 20/10/2025

We recently caught up with Tycel Phillips of @cityofhope.bsky.social, who discussed progress being made in the development of predictive biomarkers of treatment response that can be used when administering bispecifics, CAR-T, or ADCs in #lymphoma: 🎥 buff.ly/Ho867Db #LYMsm #ImmunoOnc #BloodSky

000

VJHemOnc @vjhemonc.bsky.social · 19/10/2025

To learn about the role of the immune system as a mechanism of resistance to T-cell engagers in #MultipleMyeloma, make sure to watch our recent interview from #IMS25 with Samir Parekh. 🎥🩸 Click here: 👉 buff.ly/VceerXt 👈 #MMsm #Myeloma #HemOnc #ImmunoOnc #BloodSky #HemeSky #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 18/10/2025

At #iwCLL2025, Barbara Eichhorst discussed the efficacy of epcoritamab monotherapy in first-line Richter’s transformation, highlighting 2-year follow-up results from the EPCORE CLL-1 trial. Watch the interview here: 👉 buff.ly/UvDvXD3 👈 #CLLsm #Leusm #CTSM #TrialUpdate #BloodSky #HemeSky #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 17/10/2025

🎥 In an interview from #SOHO2025, Shivani Modi shares insight into her work exploring the potential of artificial intelligence in hematologic malignancies: 👉 buff.ly/ljd6FIa 👈 #HemOnc #AI #BloodSky #HemeSky #MedSky

000

VJHemOnc @vjhemonc.bsky.social · 17/10/2025

The removal of the Risk Evaluation and Mitigation Strategy (REMS) program for CAR-T therapy is set to broaden access to CAR-T & cellular therapy outside of academic centers.💉🩸 Learn more about this in our recent interview with Muhammad Bilal Abid of @ttu.edu: 🎥 buff.ly/aPIlWiP #HemOnc #ImmunoOnc

000

VJHemOnc @vjhemonc.bsky.social · 16/10/2025

In an interview from #IMS25, Charlotte Pawlyn of @icr.ac.uk outlines ongoing UK-based clinical trials in #MultipleMyeloma, namely the FiTNESS and iFit trials. Click here to learn more: 👉 buff.ly/3qAkNKA #MMSM #HemOnc #CTSM #Myeloma #BloodSky #HemeSky #MedSky @myeloma-society.bsky.social

010

VJHemOnc @vjhemonc.bsky.social · 16/10/2025

🎥 Inga Mandac-Smoljanovic outlines the factors that affect the dose of ibrutinib administered in patients with CLL, highlighting the importance of considering comorbidities & concomitant medications when selecting a dose: 👉 buff.ly/Rs2rluB 👈 #iwCLL2025 #CLLsm #Leusm #Leukemia #HemOnc #MedSky

010

VJHemOnc @vjhemonc.bsky.social · 15/10/2025

Want to hear about the evolving role of menin inhibitors in AML?🩸 Don't miss our roundtable discussion on this topic from #iwAL25, featuring leading experts Naval Daver, @leukdocjz.bsky.social, Eytan Stein, & Amir Fathi. Watch here: 👉 buff.ly/iaEfMsV #AMLsm #Leusm #HemOnc #BloodSky #HemeSky

000